World Glaucoma Week 2015
Controlling IOP in At-Risk Populations
On March 11, AEVR held its World Glaucoma Week 2015 Congressional Briefing, co-hosted by all major glaucoma societies and research organizations (see box below). Entitled Preventing Blindness and Controlling Intraocular Pressure (IOP) in At-Risk Populations, the eventís focus was on glaucomaís public health challenges. Featured speaker Steven Mansberger, M.D., M.P.H., who serves as the Vice Chair and Director of Glaucoma Service at the Legacy Devers Eye Institute and holds an appointment at Oregon Health and Science University as Affiliate Professor of Ophthalmology and Adjunct Professor in Public Health and Preventive Medicine, spoke about his NEI and the Centers for Disease Control and Prevention (CDC)-funded research into how IOP is measured and controlled, with an emphasis on drug regimen adherence across ethnic populations.
Featured speaker Steven Mansberger, M.D., M.P.H. (Legacy Devers Eye Institute)
He described Legacy Deversí extensive glaucoma screening and detection research, which has resulted in a formula that determines if an individual will develop glaucoma in the next five years with or without medication. Although noting the usefulness of screening for elevated IOP, he also emphasized the importance of examining the optic nerve disc, since damage to it can still result even if an individual has normal tension IOP. He cited the example of Northwest Native Americans, who have a lower IOP than other ethnic groups yet are susceptible to glaucoma, likely due to optic nerve sensitivity. They have less mixing of their gene pool with Europeans than other Native Americans, and display the same low IOP glaucoma as seen in the Japanese.
Since the average glaucoma patient is treated for 14 years, a patientís compliance with their IOP-reducing drug regimen is important in disease management, especially since NEIís Ocular Hypertension Treatment Study (OHTS) found that pressure-reducing eye drops delayed disease onset. Dr. Mansberger reported that 20-80 percent of glaucoma patients have poor adherence, which includes not using the medication at designated times and using too much or too little-as in missing the eye. Risk factors for poor adherence include older age and systemic conditions (e.g. dementia), using multiple medications, lower educational level, and inadequate social support. He described Legacy Deversí research to predict compliance and develop models to improve patient adherence.
He concluded by describing various current and future treatments to lower IOP, which includes laser treatment and incisional surgery—such as a trabeculectomy—as well as minimally invasive surgeries. The latter includes development of a sustainable release medication injected into the eye which could treat it for the equivalent of three-to-six months of a daily drug regimen.
The first World Glaucoma Day was held on March 6, 2008, and the U. S. House of Representatives passed H.R. 981, which recognized the event and supported NEIís efforts to research the causes of and treatments for glaucoma. Since 2010, the day has expanded into a week of events held worldwide, with all major glaucoma professional societies and research organizations co-sponsoring AEVRís 2015 event, including:
Research to Prevent Blindness
American Glaucoma Society
Association for Research in Vision and Ophthalmology
Glaucoma Research Foundation
Optometric Glaucoma Society
The Glaucoma Foundation
Click here to read an NEI summary of its glaucoma research.
Brian Hofland, Ph.D., President of briefing co-sponsor Research to Prevent Blindness, with Dr. Mansberger
Rodney Peele, J.D., left, and Michael Duenas, O.D., right, both from the American Optometric Association, with Dr. Mansberger
Susan Berhane, from the office of Congresswoman Debbie Dingell (D-MI) speaks with Dr. Mansberger
Later that day, and under the auspices of NAEVR, Dr. Mansberger visited with Oregon delegation offices, including that of Senator Jeff Merkley (D-OR) with Alexa Damis-Wulff